Consensus $4.83. Lowers FY26 revenue view to up 1%-4% from up 3%-6%.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HAE:
- Haemonetics reports Q2 adjusted EPS $1.27, consensus $1.11
- Haemonetics (HAE) Q2 Earnings Cheat Sheet
- Haemonetics: Strategic Adjustments and Growth Potential Justify Buy Rating Despite Revenue Challenges
- Haemonetics price target lowered to $64 from $78 at Citi
- Haemonetics Poised for Recovery and Growth: Buy Rating Affirmed Amid Strategic Actions and Strong Segment Performance